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Dengue virus (DENV) is a mosquito-borne disease caused by four genetically and serologically
related viruses termed DENV-1, -2, -3 and -4. The DENV envelope (E) protein ectodomain can be
divided into three structural domains designated ED1, ED2 and ED3. The ED3 domain contains
DENV type-specific and DENV complex-reactive antigenic sites. To date, nearly all antigenic
studies on the E protein have focused on DENV-2. In this study, the epitope recognized by a
DENV-3 type-specific monoclonal antibody (mAb 14A4-8) was mapped to the DENV-3 ED3
domain using a combination of physical and biological techniques. Epitope mapping revealed that
amino acid residues V305, L306, K308, E309, V310, K325, A329, G381 and I387 were critical
for the binding of mAb 14A4-8 and amino acid residues T303, K307, K386, W389 and R391
were peripheral residues for this epitope. The location of the mAb 14A4-8 epitope overlaps with
the DENV complex-reactive antigenic site in the DENV-3 ED3 domain.
The disease dengue is caused by four serologically and
genetically related viruses, termed DENV types 1–4, which
belong to the genus Flavivirus, family Flaviviridae. Dengue
is the most important mosquito-borne viral disease in
terms of the number of cases each year and its geographical
distribution (Gubler, 2004). Over three billion people, in
more than 100 countries, are at risk from DENV infection,
with at least 50 million infections each year. The disease
DEN has several clinical manifestations including DEN
fever, DEN haemorrhagic fever (DHF) and DEN shock
syndrome (DSS) (Kurane, 2007; Leong et al., 2007; Pang
et al., 2007). Severe DHF, also known as DSS, can occur
when fluid leaks into interstitial tissue spaces, leading to
hypovolaemic shock.
The four DENVs are single-stranded, positive-sense RNA
viruses with a genome of approximately 11 kb. The
genome contains a single open reading frame encoding
three structural proteins: capsid (C), pre-membrane/
membrane (prM/M) and a major envelope glycoprotein
(E) and seven non-structural proteins (Rice et al., 1985).
The E protein is associated with viral attachment, fusion,
cellular tropism and the induction of a protective immune
response (Mukhopadhyay et al., 2005). The E protein
forms homodimers on the surface of virions and consists of
three domains: a central b-barrel (domain I: ED1), an
elongated dimerization region (domain II: ED2) and a C-
terminal immunoglobulin-like region (domain III: ED3)
(Rey et al., 1995). Among these domains, ED3 contains the
critical epitopes recognized by neutralizing antibodies. In
previous studies, we have mapped a DENV complex-
reactive (i.e. epitopes shared by the four DEN viruses only)
antigenic site for DENV-2 (Gromowski et al., 2008) and
DENV-3 (Matsui et al., 2009), and DENV type-specific (i.e.
recognized by one DENV only) antigenic site for DENV-2
(Gromowski & Barrett, 2007). These antigenic sites are
located on the lateral surface of ED3 and are recognized by
monoclonal antibodies (mAbs) with strong neutralizing
activity (Gromowski & Barrett, 2007; Gromowski et al.,
2008; Matsui et al., 2009).
Previous studies have identified DENV-3 type-specific
mAb 1H9 that was found to recognize residue 386 in ED3
by the generation of a mAb neutralization resistant variant
(Serafin & Aaskov, 2001). Recently, we reported the
identification of an antigenic site on the DENV-3 ED3
that is recognized by DENV complex-reactive mAbs. The
epitopes were characterized by a combination of physical
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mapping using rED3 mutants and biological activities of
neutralization and haemagglutination inhibition (Matsui
et al., 2009). This study showed that the critical residues
recognized by DENV complex-reactive mAbs varied
significantly for DENV-2 and DENV-3 ED3. In this study,
we have characterized an epitope on DENV-3 ED3 that is
recognized by DENV-3 type-specific mAb 14A4-8 by a
combination of physical and biological assays.
DENV-1, -2, -3 and -4 strains OBS7690, New Guinea C,
H87 and 703-4, respectively, were used in this study.
Mosquito C6/36 cells were used to propagate each of the
four DENVs. Cells were maintained at 28 uC in Dulbecco’s
modified essential medium (DMEM) containing 10% fetal
bovine serum (FBS) and supplemented with tryptose
phosphate broth (Sigma-Aldrich). Monkey kidney Vero
cells were used in plaque reduction neutralization tests
(PRNT) and were maintained in DMEM supplemented
with 8% FBS incubated at 37 uCi na5%C O 2 incubator.
mAb 14A4-8 was a kind gift of Dr Robert Putnak (WRAIR,
Silver Spring, MD, USA). The DENV complex-reactive mAb
MDVP-55A (Immunology Consultants Laboratory, Inc.),
which is known to bind to DENV-1, -2, and -3 (Matsui
et al.,2 0 0 9 )w a su s e da sac o n t r o l .
The DENV-3 rED3 was constructed and expressed as
previously described (Matsui et al., 2009). DENV-1, -2 and
-4 rED3 were also used in this study and were produced as
previously described (Gromowski & Barrett, 2007).
An indirect ELISA was used to investigate the binding of the
mAb 14A4-8 to DENV-3 rED3. A total of 27 single amino
acid substitutions were generated for DENV-3 ED3 and
evaluated using an indirect ELISA as previously described
(Gromowski & Barrett, 2007; Matsui et al., 2009).
For PRNT50, mAb 14A4-8 was diluted in PBS starting at
75 mg ml
21. Twofold serial dilutions were prepared and
mixed with an equal volume of each DENV strain (~ 50
p.f.u. per well). Virus and mAb mixtures were incubated for
1 h at 37 uC. Subsequently, the virus–mAb mixture was
transferred to approximately 80% confluent Vero cells in
six-well plates. After 30 min incubation at room temper-
ature, cell monolayers were overlaid with DMEMcontaining
2% FBS and 1% agar, and incubated at 37 uC. Plaques were
observed by staining with neutral red. PRNT50 data were
converted to per cent neutralization relative to controls; in
the absence of mAb and PRNT50, concentrations were
calculated by undertaking a non-linear regression analysis
using Sigmaplot (version 10; Systat Software, Inc.).
The Kd values are presented as mean±SEM, calculated as
previously described (Gromowski & Barrett, 2007) and were
analysed using SigmaStat (version 3.1; Systat Software, Inc.).
Statistical analysis of the experimental data and controls was
performed using the two-tailed Student’s t-test.
We were interested in mapping the DENV-3 type-specific
antigenic site of ED3 for comparison with our previous
studies that had mapped the DEN complex-reactive
antigenic site of ED3 (Matsui et al., 2009). mAb 14A4-8
was characterized physically using an indirect ELISA based
on rED3, and demonstrated specificity for the DENV-3
rED3, with a Kd of 0.58±0.15 mgm l
21 (Table 1). mAb
14A4-8 also strongly neutralized DENV-3 (PRNT50 of
14.80±4.88 mgm l
21) compared with DENV-1, -2 and -4,
which had PRNT50 values of 358.05±25.30 mgm l
21,
381.84±27.49 mgm l
21, .1500 mgm l
21, respectively.
To identify the residues involved in the epitope recognized
by mAb 14A4-8, a total of 27 single amino acid
substitutions were introduced, by site-directed mutagen-
esis, into the DENV-3 rED3 using a pMal-C2X plasmid.
Twenty-seven different surface accessible residues were
selected based on the published structure of the DENV-3 E
protein (Modis et al., 2005) and previous studies with
DENV-2 (Gromowski et al., 2008). The binding of mAb
14A4-8 was determined by titration in an indirect ELISA
with each of the 27 rED3 mutant proteins and compared to
the wild-type DENV-3 rED3 (Table 2). The importance of
residues for mAb binding was analysed as previously
described by Gromowski & Barrett (2007). Briefly, Kd
changes of between four- and tenfold were considered
‘weak’ changes and were regarded as peripheral residues in
the epitope (italics in Table 2), while Kd changes greater
than tenfold were considered ‘strong’ changes and were
regarded as critical residues in the epitope (bold in Table
2). Amino acids V305, L306, K308, E309, V310, K325,
A329, G381 and I387 were identified as critical residues for
the epitope recognized by mAb 14A4-8 (Table 2) and are
shown in red in Fig. 1(a). Amino acids T303, K307, W389
and R391 were identified as peripheral residues for the
epitope recognized by mAb 14A4-8 and are shown in pink
in Fig. 1(a). Since only a T303K substitution, and not
T303A/S, affected the binding of mAb 14A4-8 to DENV-3
ED3, T303 was considered a ‘peripheral’ residue to the
epitope.
Of the nine critical residues in the mAb 14A4-8 epitope,
four (L306, K308, G381 and I387) are identical to critical
epitope residues of four DEN complex-reactive epitopes
identified previously (Matsui et al., 2009). The other five
Table 1. Reactions of mAb 14A4-8 with different DEN viruses
Comparison of mAb 14A4-8 with each of the four DENV in rED3
ELISA and neutralization test (PRNT50). Titres are shown in
concentrations (mgm l
21).
Viruses Indirect ELISA (Kd) PRNT50
DENV-1 .1500 358.05±25.30
DENV-2 .1500 381.84±27.49
DENV-3 0.58±0.15* 14.80±4.88
DENV-4 .1500 .1500
*The P-value was compared with DENV-1, -2 and -4 (,0.05).
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identified (one type-specific in this study and four DEN
complex-reactive identified previously). mAb 14A4-8
recognizes an epitope that has a unique set of critical
epitope residues compared with any of the DENV
complex-specific epitopes identified previously. For
example, the critical residues V305, L306, K308, E309,
K325, G381 and I387 for mAb 14A4-8 were the same as
those for the DENV complex-reactive epitope recognized
by mAb MDVP-55A (Fig. 1b) (Matsui et al., 2009). In
contrast, the peripheral residues for each epitope depended
on the particular mAb, with residue K307 being specific for
the epitope recognized by mAb 14A4-8.
Although the structure of the ectodomain of DENV-3 E
protein has been resolved by X-ray crystallography, there
have been few studies on epitopes of the DENV-3 E protein
(Modis et al., 2005). We have previously reported the
mapping of DENV-3 complex-reactive epitopes on the
surface of DENV-3 rED3 (Matsui et al., 2009) and in this
report, we undertook physical and biological characteriza-
tion of the DENV-3 type-specific epitope recognized by
mAb 14A4-8 that bound to ED3 of the DENV-3 E protein.
To date only one study has mapped a type-specific epitope
on the E protein of DENV-3 (Serafin & Aaskov, 2001),
which used a mAb neutralization resistant variant to map
the epitope to residue 386 (coloured cyan in Fig. 1a). In
this study, we found that residue 386 was not part of the
epitope recognized by mAb 14A4-8, rather the critical
residues for binding of this DENV-3 type-specific mAb to
the DENV-3 rED3 were V305, L306, K308, E309, V310,
K325, A329, G381 and I387. Residues T303, K307, W389
and R391 were considered to be peripheral to the mAb
14A4-8 epitope (Fig. 1a). Since many of these residues
overlap with the previous mapping of the DENV complex-
reactive epitope recognized by mAb MDVP-55A (compare
Fig. 1a and Fig. 1b), it appears that like DENV-2 ED3
(Gromowski et al., 2008) the DENV-3 type-specific
antigenic site overlaps with the DENV complex-reactive
antigenic site on DENV-3 ED3. Furthermore, the DENV-3
type-specific and DEN complex-reactive antigenic sites
appear to be essentially on top of each other, with much
more overlap than is seen with the DENV-2 type-specific
and DEN complex-reactive antigenic sites (Gromowski
et al., 2008). This may be unique for the epitope recognized
by mAb 14A4-8 and not necessarily true for all DENV-3
ED3 type-specific epitopes, but more mAbs will be
required to test this hypothesis.
Previous studies by Sukupolvi-Petty et al. (2007) and
ourselves (Gromowski & Barrett, 2007) demonstrated that
there were two critical residues, K305 and P384, for the
DENV-2 type-specific antigenic site, which are equivalent
to residues T303 and D382 on DENV-3 ED3. Interestingly,
even though we mutated residue T303 to three different
residues and residue D382 to four different residues (Table
2), only a T303K substitution affected the binding of mAb
14A4-8 to DENV-3 ED3, suggesting that although the
DENV-3 type-specific antigenic site is on the exposed
lateral ridge of ED3, the critical residues of the DENV-3
type-specific antigenic site are not exactly analogous to
those of the DENV-2 type-specific antigenic site. This is
consistent with our previous study, demonstrating that the
residues involved in the DENV complex-reactive antigenic
site are not identical on DENV-2 and DENV-3 ED3s
(Matsui et al., 2009). Furthermore, we have shown
previously that the electrostatic charges on the surface of
each of the four DENV ED3s differ (Volk et al., 2007) and
found that more critical residues were required for binding
of both the type-specific and DEN complex-reactive
epitopes on DENV-3 (this study and Matsui et al., 2009)
compared with DENV-2 ED3 (Gromowski & Barrett, 2007;
Gromowski et al., 2008). Taking these results together, we
believe that the weaker binding of antibodies to DENV-3
ED3 compared with DENV-2 ED3 is due to differences in
surface charge (for DEN complex-reactive antibodies in
particular) and in the network of critical epitope residues
required to bind the DENV-3 and DENV-2 ED3s. If
correct, it suggests that the combination of different
residues and surface charges on the four dengue viruses
Table 2. Relative Kd for mAb/rED3 mutants using wild-type
DENV-3 strain H87 as a value of 1.0
The larger the number the weaker the binding of mAb 14A4-8 to the
rED3. ‘Critical’ residues are shown in bold and ‘weak’ residues are
shown in italic.
No. amino acid mAb 14A4-8
DENV3 wt 1.00
L301G 0.92
T303A 1.88
T303K 28.17
T303S 2.55
V305G 70.54
L306G .356.63
K307G 4.37
K308A .356.63
K308G .356.63
K308Q .356.63
E309G .356.63
V310G .356.63
K321G 1.49
K325G .356.63
A329G .356.63
G381E .356.63
D382E 0.83
D382G 1.38
D382N 1.44
D382P 1.57
K383G 1.25
A384Q 0.31
K386G 6.67
K386N 2.18
I387G 19.90
W389G 5.71
R391G 4.07
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DENVs.
The paucity of DENV-3 type-specific mAbs makes analysis
of the DENV-3 type-specific antigenic site difficult. There
is a need to have more mAbs generated against DENV-3 in
order to map additional DENV-3 type-specific epitopes on
ED3. However, it is clear that DENV type-specific and
DENV complex-reactive antigenic sites are different on
DENV-2 and DENV-3 ED3s. It would be interesting to
investigate if the same is true for all four dengue viruses.
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